Alogliptin Benzoate Raw Material Powder

Product Name: Alogliptin Benzoate Raw Material Powder

CAS: 850649-62-6

MF: C25H27N5O4

Specification​: 99% min Alogliptin Benzoate Powder

Sample:  Alogliptin Benzoate Powder

Keywords: Alogliptin Benzoate Powder,Alogliptin Benzoate Raw Material Powder,Alogliptin Benzoate Powder Supplier

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Alogliptin Benzoate Powder Usage and Synthesis:

Alogliptin Benzoate Powder, also known as alogliptin, is a serine protease dipeptidyl peptidase IV (DPP-IV) inhibitor. This product can maintain the levels of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in the body, promote the secretion of insulin, and thus play a hypoglycemic effect. The results of a randomized, placebo-controlled clinical trial showed that compared with placebo, alogliptin monotherapy can significantly improve blood sugar control in patients with type 2 diabetes, without increasing the incidence of hypoglycemia, and it is well tolerated.

Pharmacokinetics of Almotriptan Powder:
As a DPP-4 inhibitor, Alogliptin Benzoate Powder reduces the inactivation of GLP-1 in the body by selectively inhibiting DPP-4, increases the level of GLP-1 in the body, and reduces blood sugar. When blood sugar drops to a normal level, it will not continue to exert its hypoglycemic effect, so it can effectively reduce the risk of hypoglycemia. In addition, DPP-4 inhibitors can also delay gastric emptying, increase satiety, suppress appetite, and help patients lose weight. Therefore, while effectively lowering blood sugar, these drugs can also reduce the risk of hypoglycemia and weight gain, overcome the barriers for patients to reach treatment standards, and bring new hope to the treatment of diabetes.

Clinical Application of Alogliptin Benzoate Powder:
Alogliptin Benzoate Powder is generally well tolerated in patients with poorly controlled type 2 diabetes treated with or in combination with other hypoglycemic agents. The risk of hypoglycemia caused by the drug was low, ≤8.3% in the alogliptin-treated group and ≤10.5% in the placebo group, and there was no significant difference between young and elderly patients.